Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs ... Chronic rhinosinusitis with nasal polyps is a condition that can cause symptoms from sinus pain and nose stuffiness to loss of smell.

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday positive data from global KOMET Phase III trial, in which Koselugo ...

High-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

A senior AstraZeneca AZN0.91%increase; green up pointing triangle executive is under detention by Chinese authorities investigating the pharmaceutical company’s employees in the country.

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...